Lukin Medical Secures RMB 35 Million Series A Funding Led by Tongde Capital

VCBeat has learned at the earliest opportunity that Luken(Shanghai)Medical Technology Co., Ltd. (abbreviated as“Luken Medical”) announced the completion of a RMB 35 million Series A financing round. This round was led by Hermed Capital, with Shanghai Xinyoutuo Enterprise Management Co., Ltd. participating as a co-investor. The funds raised will be used for new product research and development, capacity expansion of core products, and market promotion.

Since its establishment, Luken Medical has adhered to the surgical development philosophy of “minimizing trauma,” starting with “ultra-minimally invasive” solutions and gradually expanding to cover a full portfolio of surgical products. The company is committed to researching and developing innovative “ultra-minimally invasive” medical devices that meet clinical needs.

The Company's Core MICROSUltra-minimally invasive products, available in 20 models, meet surgical needs for puncture, grasping, dissection, coagulation/sealing, and separation, and are suitable for all procedures on endoscopic surgical platforms. The product received NMPA approval and was launched in 2020. It has gained widespread favor among physicians and patients due to its advantages, including precise puncture, integrated instrument operation, small puncture diameter, and trauma-free, suture-less performance.

As endoscopic minimally invasive surgery becomes increasingly prevalent in clinical departments, and as people pursue high-quality lives characterized by surgical safety, postoperative recovery, and beautiful, scarless outcomes, MICROS holds immense growth potential. In 2019, the number of minimally invasive surgeries performed in China reached 11.9 million, and this figure is projected to increase to 26 million by 2024. The market size for minimally invasive surgical instruments and consumables in China was RMB 18.5 billion in 2019, and is expected to exceed RMB 40 billion by 2024.

Furthermore, leveraging its strengths in medical R&D and design, Luken Medical combines clinical practice insights and personalized requirements from physicians to provide customized instrument services, conceptual patent designs, and technical consultations. The company has established collaborative partnerships with clinicians from dozens of Grade A tertiary hospitals, delivering customized instruments for surgeons, obstetricians, and orthopedic specialists. By fostering deep collaboration with physicians throughout the entire process—from product concept development and prototyping to subsequent commercialization—Luken Medical bridges the gap between R&D and manufacturing, as well as between clinical practice and manufacturers. This approach truly embodies the principle of “from the clinic, back to the clinic,” achieving an integrated model of industry, academia, research, and medicine.

For this round of financing,Zhang Zhanhong, Founder of Luken Medical“Luken Medical remains committed to advancing more sophisticated solutions to alleviate patient suffering, improve quality of life post-treatment, and enhance survival rates. Luken is dedicated to developing novel medical devices with disruptive concepts, embracing challenges while focusing on professional excellence, technological innovation, and public benefit.”

Wang Xiaoying, Co-founder of Luken MedicalHe stated, “Innovation is the only way forward for the development of domestically produced medical devices. On the track of ‘ultra-minimally invasive’ technology, Luken will continue to deliver surprises. This collaboration with Hermed Capital will significantly accelerate Luken’s growth and its rapid expansion in the field of surgery. Providing doctors with a better surgical experience and alleviating patients’ pain have always been Luken’s pursuits, and we believe this will become our shared mission and goal.”

Dr. Xiao Zhenyu, Chairman of Hermed Capitalstated: “Minimally invasive surgery represents the trend in surgical development, offering numerous advantages such as reduced trauma, fewer complications, and shorter hospital stays and recovery times. It is increasingly accepted by both physicians and patients. Minimally invasive surgical instruments are a highly promising investment direction for us. As an innovative medical device R&D company, Luken Medical has successfully developed and launched its ultra-minimally invasive product M”ICROS offers advantages such as being suture-free, enabling rapid postoperative recovery, and leaving no scars. Sales have been fully launched, with applications across multiple clinical departments including urology, hepatobiliary surgery, gynecology, and thoracic surgery, earning widespread recognition and preference among clinicians. The company focuses on the field of minimally invasive surgical instruments, with multiple products in the R&D pipeline that will sequentially receive approval and market launch, bringing greater convenience to clinicians and patients. The company has established collaborations with clinical experts from dozens of Grade A tertiary hospitals in areas such as new product design, laying a solid foundation for future product development. We are honored to invest in the Luken Medical team and look forward to seeing more of its pipeline products reach the market at an early stage, thereby benefiting patients.”

Nanjing Fosun Tongrui Fund is a venture capital fund under Fosun Pharma (600196.SH, 02196.HK). Established in July 2021 with support from Nanjing Jiangbei Science & Technology Investment Group, the fund has a size of RMB 500 million and focuses on investing in early- to mid-stage biopharmaceutical companies. Hermed Capital serves as the fund manager. Hermed Capital is a VC firm specializing in biopharmaceutical investments, primarily targeting innovative drugs and innovative biotechnologies, with a focus on early-stage and growth-stage projects. The team boasts profound industry background, abundant industrial and financial resources, and a proven track record of incubating and helping portfolio companies become industry leaders. Previous investments include Henlius (HK: 02696), HaiChuang Pharma (SH: 688302), Diamedica (NASDAQ: DMAC), Aadi Bioscience (NASDAQ: AADI), Raphas (KOSDAQ: 214260), Spineology, Nico Medical, Yixin Medical, Biocytogen, Aurigene Pharmaceutical, Qumei Biology, and Bendao Gene, among others.

Xinyoutuo, engaged in fintech services, remains bullish on the development of the healthcare sector. Luken is its first medical device company investment and serves as the initial foothold for its continued investments in the healthcare field.